Abivax's IPO to fund HIV and hep B pipeline before potential Big Pharma deal
In France’s largest ever biotech IPO, Abivax has raised €58m ($64m) to continue developing its HIV and Hep B candidates.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs